STOCK TITAN

Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales of restricted Common Stock of KALA. The notice lists multiple restricted-stock lots with specific lot sizes and grant/vesting dates, including 01/30/2026 (2,450 shares) and 06/11/2025 (1,400 shares).

The filing lists additional restricted-stock lots (e.g., 397; 1,261; 800; 222; 221; 1,100 shares) tied to grant or restriction dates shown in the table. The filing is a broker notice of proposed sales under Rule 144; timing and aggregate proceeds are not stated in the provided excerpt.

Positive

  • None.

Negative

  • None.

Insights

Rule 144 notice for proposed resale of restricted shares; procedural compliance is the core action.

The filing lists multiple restricted Common Stock lots for KALA with grant/restriction dates such as 06/11/2025 and 01/30/2026 and per‑lot share counts (for example, 2,450 and 1,400 shares). The form functions as a broker notice under resale rules.

Final sale timing, aggregate amount, and purchaser details are not included in the excerpt; subsequent filings or broker confirmations would show execution and proceeds. Continued compliance with holding‑period and public‑information conditions under Rule 144 will determine whether the sales are permitted.

Administrative resale filing; market impact depends on actual sales, not the notice itself.

The entry lists multiple restricted‑stock lots by date and share count (examples: 01/30/2026 — 2,450 shares; 06/11/2025 — 1,400 shares). The form notifies the broker and regulator of intent to sell under Rule 144 constraints.

Because the form does not state aggregate proceeds or execution method, the economic effect hinges on whether and when the broker executes sales and whether selling holders satisfy holding‑period and public information conditions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the KALA Form 144 filing mean?

It notifies a broker of proposed sales of restricted Common Stock for KALA. The filing lists specific restricted lots and dates, which signal intent to resell but do not confirm actual sales or proceeds.

Which lots of KALA restricted stock are listed on this Form 144?

The filing lists multiple restricted‑stock lots with dates and counts, including 01/30/2026 for 2,450 shares and 06/11/2025 for 1,400 shares. Other lot counts are shown in the table.

Does this Form 144 mean the shares have been sold?

No; Form 144 is a notice of intent to sell under Rule 144. It does not confirm execution, aggregate proceeds, or buyer details. Actual sales may follow in separate trade reports or disclosures.

Who filed the Form 144 for KALA and what role did they list?

The broker listed is Morgan Stanley Smith Barney LLC, shown on the form as the submitting broker for proposed resale transactions. The filing records broker and security lot details but not execution outcomes.
Kala Pharmaceuticals Inc

NASDAQ:KALA

View KALA Stock Overview

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

270.48M
27.74M
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON